Bristol-Myers Squibb | BMY - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
AbbVie USD 688M 58M 2026-09
Abbott USD 297M 2M 2026-09
ALKERMES USD 27.55M 1.63M 2026-09
Amgen USD 653M 94.99B 2026-09
AstraZeneca USD 371M 31M 2026-09
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 403M 4M 2026-09
Coherus Biosciences USD 2.25M 76K 2025-12
Drreddys Laboratories INR 1.06B 113M 2026-03
Eli Lilly USD 316M 201.3M 2026-09
Gilead Sciences USD 269M 22M 2026-09
GlaxoSmithKline GBP 219M 98M 2026-09
J&J USD 43M 25M 2026-03
Medtronic USD 186M 10M 2026-06
Merck USD 525M 46M 2026-06
Novartis USD 468M 6M 2026-09
Novo Nordisk DKK 1.5B 28M 2026-06
Perrigo USD 7.48B 124.6M 2026-09
Pfizer USD 662M 5M 2026-09
Phibro Animal Health USD 11.91M 191K 2025-12
Prestige Brands USD 13.94M 2.52M 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 222M 65M 2026-09
Sanofi EUR -25M 99.78M 2025-12
United Therapeutics USD 2.9M 0 2026-09
Zoetis USD 62M 1000K 2026-09